摘要
肺动脉高压（pulmonary artery hypertension，PAH）是各种原因引起的肺动脉压力持续升高的临床综合征，最终可导致右心衰竭以及死亡。微小RNA（microRNAs，miRNAs）是真核细胞中一大类参与基因转录后调控的非编码小分子RNA。miRNAs通过参与BMP／Smad通路、Src／STAT3／Pim1通路、缺氧诱导因子-1α与P53等信号通路的调控，影响PAH的发生发展。PAH时，肺组织中某些miRNAs表达可出现明显下调（miR-45l和miR-124等）或上调（miR-23b、miR-130a和miR-191等），可能是PAH的早期诊断生物标记物，对miRNAs与PAH的关系的深入研究可能为PAH的临床诊疗提供新的思路与靶点。
Pulmonary arterial hypertension （PAH） is a debilitating disease characterized by progressive obstruction and obliteration of the pulmonary arteries ultimately leading to a progressive rise in pulmonary vascular resistance and right ventricular failure and death. MicroRNAs （miRNAs） are a class of small non-coding RNAs which involve in the regulation after gene transplantation. MiRNAs affect the development of PAH through participation in BMP/Smad pathway, Src/STAT3/Piml pathway, hypoxia-inducible factor-1α and P53 signaling pathway. Studies have shown that several novel downregulated miRNAs （miR-451, miR-124） and upregulated miRNAs （miR-23b, miR-130a and miR- 191） appear in the circulation of PAH subjects. These miRNAs may be considered as potential biomarker for early diagnosis of PAH. Further investigation of the relationship between miRNAs and PAH will provide new ideas and targets for the diagnosis and treatment of PAH.
出处
《国际呼吸杂志》
2015年第9期706-709,共4页
International Journal of Respiration
基金
国家自然科学基金（81273571）
江苏省人事厅六大人才高峰（2008074）
江苏省科技厅科技支撑计划（BE2011801）
江苏省呼吸病临床医学研究中心（BL2012012）
